Clinical Trials Logo

Squamous Cell Lung Cancer clinical trials

View clinical trials related to Squamous Cell Lung Cancer.

Filter by:

NCT ID: NCT02288026 Recruiting - Clinical trials for Squamous Cell Lung Cancer

Comparison of Different Types of Surgery in Treating Patients With Early-stage Non-small Cell Lung Cancer

Start date: September 2014
Phase: N/A
Study type: Observational

The purpose of this study is to compare early-stage peripheral non-small cell lung cancer lobectomy and sub-lobectomy surgery to evaluate if sub-lobectomy is as feasible and effective for the treatment of early-stage (diameter ≤2cm) peripheral non-small cell lung cancer as lobectomy.

NCT ID: NCT02264210 Recruiting - Lung Neoplasms Clinical Trials

Icotinib for Completed Resected IB NSCLC With EGFR Mutation

CORIN
Start date: January 2015
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well icotinib works in treating patients with completely resected stage IB NSCLC harboring EGFR mutation.

NCT ID: NCT01801852 Recruiting - Breast Cancer Clinical Trials

Autologous Natural Killer T Cells Infusion for the Treatment of Cancer

Start date: January 2013
Phase: N/A
Study type: Interventional

The purpose of this study is to assess the safety and effectiveness of natural killer T (NKT) cell-based autologous adoptive immunotherapy in subjects with metastatic, treatment-refractory breast cancer, glioma, hepatocellular carcinoma, squamous cell lung cancer, pancreatic cancer, colon cancer or prostate cancer.

NCT ID: NCT01660399 Recruiting - Clinical trials for Squamous Cell Lung Cancer

Clinical Trial of Boanmycin Hydrochloride With Docetaxel for Patients With Lung Squamous Cell Cancer as Chemotherapy

Start date: August 2012
Phase: Phase 2
Study type: Interventional

This predictive, randomized, double-blind, multi-center trial is going to evaluate the efficacy and safety of two regimens of boanmycin plus docetaxel versus docetaxel alone as a second line treatment for chemotherapy for stage IIIb-IV or postoperative recurrent squamous cell lung cancer patients.